Cardiovascular & Metabolic Pipeline Clinical Trials Interactive
Learn about Amgen’s active cardiovascular and metabolic pipeline clinical trials in atherosclerotic cardiovascular disease (ASCVD), obesity, and nonalcoholic steatohepatitis (NASH).
Welcome to the Amgen Medical Virtual Exhibit
Cardiovascular & Metabolic Pipeline
Evolocumab PROFICIO Program and Ongoing Trials Book
Learn about PROFICIO, Amgen’s program of clinical studies of evolocumab, including VESALIUS-CV, a global initiative exploring the potential of evolocumab for the prevention of first CV events. This is an investigational study. Evolocumab is not indicated for this intended use.
Evolocumab PROFICIO Real-World Evidence (RWE) Generation Booklet
Evolocumab PROFICIO RWE is Amgen's program of real-world evidence studies investigating the impact of evolocumab and use of lipid-lowering therapies across multiple patient populations.
Evolocumab VESALIUS-CV Clinical Trial Card
A double-blind, randomized, placebo-controlled, Phase 3, multicenter study to evaluate the impact of evolocumab on major cardiovascular events in patients at high cardiovascular risk without prior myocardial infarction or stroke. This is an investigational study. Evolocumab is not indicated for this intended use.
Evolocumab EVOLVE-MI Clinical Trial Card
An open-label, randomized, multicenter, pragmatic study to evaluate early treatment with evolocumab plus routine lipid management vs routine lipid management alone in patients hospitalized for an acute myocardial infarction. This is an investigational study.
Olpasiran (AMG 890) Phase 3 Clinical Trial Card
A phase 3 double-blind, randomized, placebo-controlled, multicenter study assessing the impact of olpasiran on major CV events in participants with ASCVD and elevated lp(a). Olpasiran is an investigational drug. Efficacy and safety have not been established.
Lp(a) Prevalence Clinical Trial Card
A multicenter, cross-sectional, single-group study to characterize the distribution of Lp(a) levels among patients with documented history of ASCVD.
AMG 133 Phase 2 Clinical Trial Card
A phase 2 randomized, placebo-controlled, double-blind, dose-ranging study to evaluate the efficacy, safety and tolerability of AMG 133 in adult subjects with overweight or obesity, with or without type 2 diabetes mellitus. AMG 133 is an investigational drug. Efficacy and safety have not been established.
Amgen Pipeline Website
Explore Amgen's robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illnesses.
Amgen Clinical Trials
AmgenTrials.com is dedicated to bringing information about Amgen's clinical trials to patients and healthcare communities.
Please note: Some of the information on this page may pertain to investigational drugs.